

MiRXES, J&J and Janssen unites for early detection of lung cancer

10 January 2018 | News

MiRXES to Collaborate with Johnson & Johnson Innovation LLC and Janssen Pharmaceutica to Advance Biomarker Diagnostics for Lung Cancer



MiRXES has announced a strategic collaboration with Johnson & Johnson Innovation and Janssen Pharmaceutica NV to further develop a novel circulating miRNA diagnostic test, with the aim to improve the detection of early-stage lung cancer.

This is among the 15 new strategic collaborations by Johnson & Johnson Innovation to drive innovation in science and technology to address areas of high unmet medical needs.

Dr Lihan Zhou, Co-founder and CEO of MiRXES said, "Lung cancer is the most prevalent and deadliest cancer globally, with close to 2 million new cases annually. Prognosis remains poor due to late manifestation and diagnosis. We are excited to collaborate with the world's largest healthcare innovation company to advance the science and technology of miRNA as a novel solution for lung cancer screening and diagnosis. The goal is to develop and commercialize an accurate, affordable and actionable blood test to detect lung cancer at early and asymptomatic stage."

Dr Zhou will present the development roadmap of MIRXES' lung and other cancer miRNA assays at the reputed Biotech Showcase 2018 during the JPM week at San Francisco.